VCM
GALT icon

Vivaldi Capital Management’s Galectin Therapeutics GALT Stock Holding History

Vivaldi Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$721K Buy
258,584
+54,514
+27% +$166K 0.1% 127
2025
Q4 		$849K Sell
204,070
-51,682
-20% -$272K 0.12% 115
2025
Q3 		$1.08M Buy
255,752
+83,309
+48% +$313K 0.15% 106
2025
Q2 		$364K Buy
172,443
+116,815
+210% +$175K 0.05% 196
2025
Q1 		$67.9K Buy
55,628
+10,000
+22% +$14K 0.01% 279
2024
Q4 		$55.7K Buy
45,628
+21,596
+90% +$51.8K 0.01% 283
2024
Q3 		$66.1K Hold
24,032
– – 0.02% 224
2024
Q2 		$54.3K Hold
24,032
– – 0.02% 228
2024
Q1 		$72.8K Buy
24,032
+4,771
+25% +$9.03K 0.02% 219
2023
Q4 		$32.6K Hold
19,261
– – 0.01% 219
2023
Q3 		$37K Hold
19,261
– – 0.01% 193
2023
Q2 		$27.7K Hold
19,261
– – 0.01% 200
2023
Q1 		$40.4K Hold
19,261
– – 0.01% 200
2022
Q4 		$22.5K Hold
19,261
– – 0.01% 241
2022
Q3 		$30K Buy
19,261
+2,183
+13% +$4.08K 0.01% 220
2022
Q2 		$22K Hold
17,078
– – 0.01% 216
2022
Q1 		$23K Buy
17,078
+6,410
+60% +$12.4K 0.01% 213
2021
Q4 		$22K Hold
10,668
– – 0.01% 207
2021
Q3 		$41K Hold
10,668
– – 0.01% 333
2021
Q2 		$36K Hold
10,668
– – 0.01% 343
2021
Q1 		$45K Sell
10,668
-4,771
-31% -$10.7K 0.01% 357
2020
Q4 		$35K Hold
15,439
– – 0.01% 302
2020
Q3 		$42K Hold
15,439
– – 0.01% 275
2020
Q2 		$40K Buy
15,439
+4,771
+45% +$12K 0.01% 259
2020
Q1 		$21K Hold
10,668
– – ﹤0.01% 195
2019
Q4 		$31K Hold
10,668
– – 0.01% 209
2019
Q3 		$39K Hold
10,668
– – 0.01% 216
2019
Q2 		$44K Buy
+10,668
New +$46.2K 0.01% 227

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Vivaldi Capital Management's GALT Position: Q1 2026 in Review

Vivaldi Capital Management increased its Galectin Therapeutics (GALT) stake by 27% in Q1 2026, buying an estimated $166K and bringing the position to 258,584 shares worth $721K. The position accounts for 0.1% of the portfolio, ranked #127.

Vivaldi Capital Management first reported a position in GALT in Q2 2019 and has held it in 28 quarters since. The position peaked at $1.08M in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Vivaldi Capital Management held 258,584 shares of Galectin Therapeutics worth $721K as of Q1 2026.
  • Vivaldi Capital Management bought 54,514 Galectin Therapeutics shares in Q1 2026, an estimated $166K.
  • Galectin Therapeutics made up 0.1% of Vivaldi Capital Management's portfolio in Q1 2026, its #127 holding.
  • Vivaldi Capital Management first reported a position in Galectin Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Vivaldi Capital Management's Galectin Therapeutics position peaked at $1.08M in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Vivaldi Capital Management's 13F filing for Q1 2026, filed 14 May 2026.